Rising Pharma Holdings, Inc.

Rising Pharma Holdings, Inc., operating under the trade name Rising Pharmaceuticals, is a privately held pharmaceutical company headquartered in East Brunswick, New Jersey. Established in 1990, the company specializes in the marketing and distribution of generic prescription and over-the-counter (OTC) pharmaceutical products across the United States. Their diverse portfolio encompasses a wide range of therapeutic areas and multiple dosage forms, including tablets, capsules, syrups, and injections. Rising Pharmaceuticals is committed to delivering high-quality, accessible medications, ensuring that every product undergoes rigorous quality assurance protocols to meet regulatory standards.

In April 2019, Rising Pharma Holdings, Inc. acquired the assets of Rising Pharmaceuticals, Inc., a company based in Saddle Brook, New Jersey, which had filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in February 2019. This acquisition allowed Rising Pharma Holdings to expand its product offerings and strengthen its position in the U.S. pharmaceutical market. The company's leadership team comprises industry experts with extensive experience in pharmaceutical development, marketing, and distribution, driving innovation and ensuring the highest standards of care for patients.

Rising Pharmaceuticals operates a comprehensive distribution network across the United States, ensuring the efficient delivery of its pharmaceutical products to various stakeholders, including wholesalers, chain drug stores, distributors, and mass merchandisers. The company's logistics capabilities are designed to maintain a reliable supply chain, facilitating timely and secure delivery of products nationwide. While specific warehouse locations are not publicly disclosed, Rising Pharmaceuticals emphasizes its commitment to quality and customer service, indicating a well-established infrastructure to support its distribution operations.

Rising Pharmaceuticals plays a significant role in the U.S. pharmaceutical supply chain as a pharmaceutical importer and distributor. By sourcing generic prescription and OTC products from various manufacturers, including those in India, the company ensures a steady supply of affordable medications to the U.S. market. Their operations bridge the gap between international manufacturers and domestic consumers, contributing to the accessibility and affordability of healthcare in the United States.

Rising Pharmaceuticals demonstrates a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $87.0 million USD from India, encompassing 4,132 shipments across 18 products in 11 therapeutic categories. The top five products imported include Gabapentin ($21.2 million), Furosemide ($14.0 million), Ondansetron ($13.2 million), Pioglitazone ($8.3 million), and Escitalopram ($4.7 million), collectively accounting for 70.5% of the total import value. This concentration indicates a strategic focus on specific high-demand products, potentially leveraging favorable pricing and manufacturing capabilities in India. However, such dependency on a limited number of suppliers and products may expose Rising Pharmaceuticals to risks related to supply chain disruptions, regulatory changes, or market fluctuations affecting these key products.

Rising Pharmaceuticals' supply chain resilience is influenced by its sourcing strategy, which heavily relies on imports from India. The company's top suppliers include AUROBINDO PHARMA LIMITED, GRAVITI PHARMACEUTICALS PRIVATE LIMITED, and J B CHEMICALS AND PHARMACEUTICALS LIMITED, collectively accounting for a substantial portion of the import value. While these partnerships may offer cost advantages and access to a diverse range of products, the concentration of suppliers poses potential risks. Factors such as geopolitical tensions, regulatory changes, or disruptions in manufacturing capabilities in India could impact the stability of the supply chain. To enhance resilience, Rising Pharmaceuticals may consider diversifying its supplier base, establishing backup suppliers, and ensuring compliance with international quality standards to mitigate potential disruptions.

Rising Pharmaceuticals' sourcing pattern, characterized by a high concentration of imports from India, positions the company to benefit from cost-effective manufacturing and a diverse product range. This strategy enables the company to offer competitive pricing and a broad portfolio to the U.S. market. However, the reliance on a limited number of suppliers and products may expose Rising Pharmaceuticals to supply chain vulnerabilities. For Indian exporters, this presents an opportunity to strengthen relationships with Rising Pharmaceuticals by ensuring consistent product quality, timely delivery, and compliance with regulatory standards. By addressing these factors, Indian suppliers can enhance their appeal as reliable partners, potentially increasing their share in Rising Pharmaceuticals' sourcing strategy.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and marketing of pharmaceutical products. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drug applications, including Abbreviated New Drug Applications (ANDAs) for generic drugs. The Federal Food, Drug, and Cosmetic Act (FDCA) and the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) are key legislative frameworks governing the approval and marketing of generic drugs in the U.S. These regulations ensure that imported pharmaceutical products meet safety, efficacy, and quality standards before reaching the U.S. market.

Import licensing requirements for pharmaceutical products entering the United States are stringent. All imported drugs must be approved by the FDA, which involves submitting an ANDA for generic drugs. Manufacturers must adhere to Good Manufacturing Practice (GMP) standards, which are recognized by the FDA. While the FDA does not have a formal mutual recognition agreement with the European Union, it does accept GMP certifications from countries with which it has established agreements, provided they meet FDA standards. Wholesale distributors like Rising Pharmaceuticals must obtain appropriate licenses to operate, ensuring compliance with federal and state regulations governing the distribution of pharmaceutical products.

Imported pharmaceutical products must undergo batch testing to verify their identity, strength, quality, and purity. Stability studies are required to determine the shelf life and storage conditions of the products. Labeling requirements include the use of English language, with specific information such as drug name, dosage form, strength, directions for use, and storage conditions. Serialization mandates, such as the Drug Supply Chain Security Act (DSCSA), require the tracking and tracing of prescription drugs to enhance security and prevent counterfeit products from entering the supply chain.

Between 2024 and 2026, the FDA has implemented several policy changes affecting the importation of pharmaceutical products from India. These include enhanced scrutiny of manufacturing facilities, increased inspections, and stricter enforcement of GMP compliance. Additionally, the FDA has updated labeling requirements to include more detailed information on product origins and manufacturing processes. These changes aim to improve the safety and quality of imported pharmaceutical products and may impact the sourcing strategies of companies like Rising Pharmaceuticals.

Rising Pharmaceuticals' product strategy focuses on high-demand therapeutic areas, including Central Nervous System (CNS) & Psychiatric disorders, Diuretics, and Gastrointestinal conditions. The company's top five imported products—Gabapentin, Furosemide, Ondansetron, Pioglitazone, and Escitalopram—align with these therapeutic categories, indicating a strategic emphasis on addressing prevalent health issues. Market demand for these products is driven by the widespread prevalence of conditions such as epilepsy, hypertension, heart failure, nausea, diabetes, and depression, necessitating accessible and effective treatment options.

Rising Pharmaceuticals' sourcing strategy centers on generic drugs, with a preference for finished pharmaceutical formulations over raw Active Pharmaceutical Ingredients (APIs). This approach allows the company to offer a diverse product portfolio without the complexities associated with API sourcing and manufacturing. India's well-established pharmaceutical industry, characterized by a large number of manufacturers and a broad range of products, makes it a strategic sourcing partner for Rising Pharmaceuticals.

Based on its product mix, Rising Pharmaceuticals serves multiple segments of the U.S. pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's diverse portfolio enables it to meet the needs of various healthcare providers and consumers, contributing to the accessibility and affordability of medications across the United States.

There is a realistic opportunity for new Indian suppliers to enter Rising Pharmaceuticals' sourcing network. The company's significant import volume from India and its focus on high-demand therapeutic areas indicate a potential for expanding supplier relationships. Gaps in Rising Pharmaceuticals' current sourcing may include a need for additional suppliers in specific product categories or for products that meet evolving regulatory standards.

Indian exporters seeking to supply Rising Pharmaceuticals and the U.S. market must ensure compliance with FDA regulations, including obtaining ANDA approvals for generic drugs. Manufacturers must adhere to GMP standards recognized by the FDA, and products must meet labeling and serialization requirements. Establishing a reliable supply chain and demonstrating a commitment to quality assurance are essential for gaining entry into